Caitong International Asset Management Co. Ltd Sells 25,537 Shares of Hims & Hers Health, Inc. $HIMS

Caitong International Asset Management Co. Ltd lowered its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 88.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,355 shares of the company’s stock after selling 25,537 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Hims & Hers Health were worth $190,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after acquiring an additional 200 shares during the period. GAMMA Investing LLC lifted its holdings in Hims & Hers Health by 6.1% during the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC lifted its holdings in Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after purchasing an additional 252 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares during the period. Finally, W.G. Shaheen & Associates DBA Whitney & Co boosted its stake in Hims & Hers Health by 4.8% in the 3rd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock valued at $436,000 after purchasing an additional 350 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $25.02 on Wednesday. The company has a market cap of $5.70 billion, a price-to-earnings ratio of 49.06, a PEG ratio of 2.42 and a beta of 2.55. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a fifty day moving average price of $23.43 and a 200-day moving average price of $37.08.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business earned $0.11 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the transaction, the chief financial officer directly owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This trade represents a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 41,227 shares of company stock worth $1,406,343. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HIMS shares. Leerink Partners increased their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday. TD Cowen reduced their target price on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research report on Tuesday, February 24th. Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and upped their price target for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Morgan Stanley dropped their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a report on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.29.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk partnership increases HIMS’ addressable market by giving HIMS platform access to Ozempic and Wegovy via telehealth, resolves public dispute and could drive patient volumes and revenue growth. Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
• Positive Sentiment: The telehealth deal is framed as strategic distribution for branded GLP-1s and may broaden patient access through HIMS’ platform — a near-term revenue catalyst if patient onboarding scales. Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
• Positive Sentiment: HIMS is expanding beyond telehealth into personalized digital care (labs tracking, multi-cancer screening, longevity and at-home testing) and international growth — diversification that can build higher-margin services and reduce reliance on episodic telehealth visits. HIMS Expands Personalized Digital Healthcare Access and Services
• Neutral Sentiment: Analysts note GLP-1 winners may be decided by pricing as Lilly and Novo push competitive moves; lower branded prices could boost demand but compress margins — mixed implications for HIMS’ economics. Health Care Roundup: Market Talk
• Neutral Sentiment: Leerink raised HIMS’ price target to $25 and kept a “market perform” rating — a modest signal that near-term upside is viewed as limited by some sell-side analysts. Leerink Raises Price Target
• Negative Sentiment: Shares pulled back after a recent 50% one-month surge, suggesting short-term profit-taking and continued volatility; investors should expect swings as GLP-1 access and pricing dynamics play out. Hims & Hers Health stock slips after surging 50% in a month

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.